Apyx Medical Corporation (NASDAQ:APYX) Receives $6.50 Consensus Target Price from Analysts

Apyx Medical Corporation (NASDAQ:APYX) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $6.50.

Several brokerages have commented on APYX. Craig Hallum upped their target price on shares of Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. BTIG Research upgraded shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Friday, March 27th. Finally, Wall Street Zen cut shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th.

Institutional Trading of Apyx Medical

A number of large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC increased its position in shares of Apyx Medical by 19.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after buying an additional 636,043 shares in the last quarter. Royce & Associates LP increased its position in shares of Apyx Medical by 1.4% in the 3rd quarter. Royce & Associates LP now owns 2,474,399 shares of the company’s stock valued at $5,295,000 after buying an additional 34,696 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Apyx Medical by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock valued at $3,272,000 after buying an additional 53,175 shares in the last quarter. AIGH Capital Management LLC bought a new stake in shares of Apyx Medical in the 4th quarter valued at $3,867,000. Finally, Silverberg Bernstein Capital Management LLC increased its position in shares of Apyx Medical by 0.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock valued at $3,842,000 after buying an additional 8,067 shares in the last quarter. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Stock Performance

Shares of Apyx Medical stock opened at $3.99 on Monday. The firm has a fifty day moving average of $3.80 and a two-hundred day moving average of $3.79. The stock has a market capitalization of $167.06 million, a price-to-earnings ratio of -18.14 and a beta of 1.39. Apyx Medical has a 52 week low of $1.41 and a 52 week high of $4.50. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.06. The company had revenue of $12.49 million during the quarter, compared to analysts’ expectations of $10.53 million. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.